On the last day of the public comment period for CMS’s Aduhelm coverage proposal, former pediatrician Alan Schooley, now living with early-onset Alzheimer’s, shares…
The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects…
Voices of Alzheimer’s is a new organization dedicated to elevating the stories of people living with the disease. Here’s how VOA’s 5 founders —…
Medicare coverage of Alzheimer’s drug Aduhelm may soon be dramatically limited. The CMS is asking for public comments before finalizing the decision. Last week,…
It seems like, following the FDA’s controversial July 2021 approval of Biogen’s Alzheimer’s drug Aduhelm, everyone is mad at someone. Here are the main…
Aduhelm’s clinical trials shines a light on why representation is crucial in the search for effective Alzheimer’s treatments. The Food and Drug Administration’s (FDA)…
European drug regulators dealt a blow to Biogen, deciding against allowing Aduhelm onto the market. Meanwhile, the company slashed the price of its drug…